DCFPYL

For research use only. Not for therapeutic Use.

  • CAT Number: I025608
  • CAS Number: 1423758-00-2
  • Molecular Formula: C18H23FN4O8
  • Molecular Weight: 442.4
  • Purity: ≥95%
Inquiry Now

DCFPYL (Cat.No:I025608) is a PSMA-targeted PET imaging agent for prostate cancer. Inquire DCFPYL online by filling out the inquiry form, we will get back to you within 24 hours!


Catalog Number I025608
CAS Number 1423758-00-2
Synonyms

DCFPYL;

Molecular Formula C18H23FN4O8
Purity ≥95%
Target PSMA
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).
IUPAC Name (((S)-1-carboxy-5-(6-fluoronicotinamido)pentyl)carbamoyl)-L-glutamic acid
InChI InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1
InChIKey OLWVRJUNLXQDSP-RYUDHWBXSA-N
SMILES O=C(O)CC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCCCNC(C1=CC=C(F)N=C1)=O)=O
Reference

1: Bouvet V, Wuest M, Bailey JJ, Bergman C, Janzen N, Valliant JF, Wuest F. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile. Mol Imaging Biol. 2017 Dec;19(6):923-932. doi: 10.1007/s11307-017-1102-x. PubMed PMID: 28639122.
2: Basuli F, Zhang X, Woodroofe CC, Jagoda EM, Choyke PL, Swenson RE. Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination. J Labelled Comp Radiopharm. 2017 Mar;60(3):168-175. doi: 10.1002/jlcr.3487. Epub 2017 Feb 1. PubMed PMID: 27990672; PubMed Central PMCID: PMC5344719.
3: Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26. PubMed PMID: 27889802; PubMed Central PMCID: PMC5323462.
4: Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C Jr, Ponnala S, Babich JW. Synthesis and pre-clinical evaluation of a new class of high-affinity (18)F-labeled PSMA ligands for detection of prostate cancer by PET imaging. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):647-661. doi: 10.1007/s00259-016-3556-5. Epub 2016 Nov 15. PubMed PMID: 27847991; PubMed Central PMCID: PMC5323493.
5: Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol. 2015 Aug;17(4):575-84. doi: 10.1007/s11307-015-0866-0. PubMed PMID: 26013479; PubMed Central PMCID: PMC4493776.

Request a Quote